U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188558) titled 'A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy' on Sept. 16.
Brief Summary: This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Large B-cell Lymphoma
Lymphoma, B-Cell
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma Refractory/ Relapsed
Diffuse Large B Cell Lymphoma (...